HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer

ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium

Merck’s KEYTRUDA–Padcev combo delivers survival gains in Phase 3 bladder cancer trial

Eli Lilly’s retatrutide delivers breakthrough results in obesity & knee osteoarthritis trial

Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints

New oral SERD from Roche delivers significant survival edge in early breast cancer

At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival

Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy

Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib

Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial

The trial tested six injectable doses and three oral doses over as long as 36 weeks

Gilead delivers groundbreaking HIV prevention drug to Eswatini & Zambia

The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval

FDA slaps gene therapy Elevidys with boxed warning after fatal liver failures

Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels

Tata 1mg boosts delivery speed with AI-driven logistics

This partnership has led to a 10% boost in delivery speed

AstraZeneca delivers double-digit growth

The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy